查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1840571

全球流感疫苗市场（依疫苗类型、年龄层、剂量、剂型、通路和最终用户划分）－2025-2032年预测

Influenza Vaccine Market by Vaccine Type, Age Group, Dosage, Presentation, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，流感疫苗市场规模将达到 175.4 亿美元，年复合成长率为 9.29%。

主要市场统计数据
基准年 2024 86.1亿美元
预计年份：2025年 94.1亿美元
预测年份：2032年 175.4亿美元
复合年增长率 (%) 9.29%

策略实施：建构技术创新、供应链韧性与政策动态整合框架，共同影响流感疫苗决策

流感疫苗领域正经历快速变革，其驱动力包括技术创新、人口结构变化以及供应链监管的加强。随着公共卫生计画和私人企业调整优先事项，决策者越来越关注疫苗平台、供应形式和分销管道如何与监管预期和支付方动态相协调。本次交流重点在于以下几个关键主题，这些主题将为后续分析提供参考：抗原设计和生产平台的创新、低温运输和剂型选择的营运实际情况，以及针对影响疫苗供应和成本状况的政策和贸易发展而采取的战略应对措施。

在此背景下，相关人员面临着更为复杂的风险矩阵：医疗设备製造商正在将新一代平台与现有产能相整合；医疗系统正在重新思考疫苗接种管道，以优化不同年龄层的接种率；采购机构则在韧性和成本效益之间寻求平衡。这些动态凸显了供应连续性和采购可预测性之间的矛盾，同时也为差异化供应解决方案、有针对性的疫苗接种策略以及公私合作干预措施提供了机会。这些动态凸显了进行精细化市场细分、考虑区域差异以及重点分析关税相关变化的重要性，也说明了策略敏捷性对于保持竞争力至关重要。

这项介绍性的观点为更深入的探讨奠定了基础，结合了技术、商业性和政策视角，帮助读者了解短期营运决策如何与流感疫苗生态系统中的长期策略成果相对应。

平台多元化、交付创新和供应链现代化如何重塑流感疫苗市场动态和相关人员策略

流感疫苗领域正经历变革性的转变，不仅体现在产品的逐步更新，也体现在生产架构、给药方式以及相关人员的合作模式等方面。灭活疫苗的生产仍在不断优化产能和产量，而减毒活病毒疫苗疫苗和重组疫苗则因其能够提供更广泛的免疫反应和更短的生产週期而日益受到关注。同时，人们也越来越重视那些易于给药且能减少浪费的给药形式，例如采用不同材料的预填充式注射器和专为灵活给药策略设计的管瓶。

除了产品创新之外，系统性变革也正在重塑相关人员的行为。支付方和公共卫生机构正努力将人口风险评估与疫苗接种计划相匹配，从而鼓励更精细地关注不同年龄层的策略。同时，契约製造和灌装包装专业化正在加速发展，使规模较小的创新者和区域製造商无需在上游抗原生产方面进行大量资本投资即可扩大规模。供应链数位化和低温运输现代化正在实现更严格的库存控制和即时可视性，从而减少缺货并实现更快捷的配送模式。

这些转变伴随着监管和公共卫生框架的演变，这些框架优先考虑快速反应能力和公平获取。其累积效应是形成了一个奖励适应性、跨伙伴关係以及对平台多功能性和交付优化进行投资的市场环境。相关人员将获得价值，并支持具有韧性的免疫规划。

评估2025年美国关税变化对疫苗价值链筹资策略、在地化生产和供应链韧性的多面向影响

2025年美国关税调整的累积影响正波及整个流感疫苗生态系统，波及采购决策、投入成本与供应链设计。依赖跨境采购专用耗材、注射器组件和填充包装材料的生产商面临更高的到岸成本和更长的采购週期。这些变化促使企业采取了一系列应对战术性，包括供应商多元化、重新谈判长期合约以及在地采购关键组件，以降低贸易政策变化带来的波动。

这些主导压力也加速了围绕区域製造能力和本土化策略的讨论。商用设计的设施变得更具吸引力，成为减轻跨境关税对成品影响的有效途径；同时，抗原生​​产商越来越多地与区域契约製造组织合作，以最大限度地减少关税漏洞。此外，生产商也正在评估不同製剂形式之间的成本权衡。对一些生产商而言，可共用分销成本的多剂量管瓶在经济上是可行的；而另一些生产商则优先考虑预填充式注射器製剂形式减少给药时间和浪费，并愿意接受更高的原料成本以确保市场差异化。

除了直接的成本影响外，关税环境也加剧了监管和合约审查的力度。采购团队正在重新审视不可抗力条款、转嫁条款和供应连续性条款，监管机构也正与业界合作，确保贸易措施不会无意中阻碍公共卫生防控工作。这促使企业加大对供应链透明度、情境规划和供应商风险评估的投入，并采取更谨慎的采购策略。积极调整筹资策略和合约框架的企业，将更有能力在贸易逆风中维持疫苗接种计画的连续性。

以细分市场主导的策略洞察，揭示疫苗类型、年龄层、剂量、剂型、分销管道和最终用户特征如何相互作用，从而影响疫苗的商业化和供应。

透过細項分析获得的洞见揭示了不同疫苗类型、年龄层、剂量、剂型、分销管道和最终用户群体所面临的差异化机会空间和营运重点。在疫苗类型方面，灭活疫苗、减毒活病毒疫苗疫苗和重组疫苗之间的差异对于生产前置作业时间、低温运输敏感性和临床指导至关重要，这些因素也会影响采购计划和临床培训需求。在年龄层方面，成人、老年人和儿童群体需要个人化的传播策略、剂量考量和推广模式，以优化疫苗接种率并最大限度地减少不利事件的发生。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大mRNA技术在四价和通用开发的应用
  • 采用高剂量和佐剂疫苗配方增强老年族群的免疫抗原性
  • 实施即时监测和报告流感疫苗效力的数位健康平台
  • 加速监管核准和紧急使用授权可加速新型流感疫苗候选物的研发。
  • 製药公司与当地生产商进行策略合作，以解决区域疫苗短缺问题

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以疫苗类型分類的流感疫苗市场

  • 惰性
  • 减毒活病毒疫苗
  • 重组

第九章 依年龄组别分類的流感疫苗市场

  • 成人
  • 老年人
  • 孩子们

10. 依剂量分類的流感疫苗市场

  • 多次给药
  • 单一剂量

第十一章 流感疫苗市场（以展示方式划分）

  • 预填充式注射器
    • 玻璃预填充式注射器
    • 塑胶预填充式注射器
  • 管瓶
    • 多剂量管瓶
    • 单剂量管瓶

第十二章 流感疫苗市场（依通路划分）

  • 直销
  • 医院药房

第十三章 依最终用户分類的流感疫苗市场

  • 诊所
    • 门诊部
    • 专科诊所
  • 医院
    • 私立医院
    • 公立医院

第十四章 各地区流感疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 流感疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国流感疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Sanofi SA
    • CSL Limited
    • GlaxoSmithKline plc
    • AstraZeneca plc
    • Pfizer Inc.
    • Sinovac BIoTech Ltd.
    • China National Pharmaceutical Group Co., Ltd.
    • Serum Institute of India Private Limited
    • Changchun BCH Bioengineering Co., Ltd.
    • Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
Product Code: MRR-032A67D913E1

The Influenza Vaccine Market is projected to grow by USD 17.54 billion at a CAGR of 9.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.61 billion
Estimated Year [2025] USD 9.41 billion
Forecast Year [2032] USD 17.54 billion
CAGR (%) 9.29%

A strategic introduction framing the convergence of technological innovation, supply chain resilience, and policy dynamics shaping influenza vaccine decision-making

The influenza vaccine landscape is evolving at pace, driven by technological innovation, shifting demographics, and intensified supply chain scrutiny. As public health programs and commercial players recalibrate priorities, decision-makers increasingly demand clarity on how vaccine platforms, delivery formats, and distribution pathways intersect with regulatory expectations and payer dynamics. This introduction frames the central themes that will inform subsequent analysis: innovation in antigen design and manufacturing platforms, the operational realities of cold chain and presentation choices, and the strategic responses to policy and trade developments that influence availability and cost profiles.

Against this backdrop, stakeholders are contending with a more complex risk matrix. Manufacturers are integrating next-generation platforms with legacy capacities, healthcare systems are revisiting immunization pathways to optimize uptake across diverse age cohorts, and procurement entities are balancing resilience against cost efficiency. The convergence of these forces creates both tension and opportunity: tension in supply continuity and procurement predictability, and opportunity in differentiated delivery solutions, targeted immunization strategies, and collaborative public-private interventions. Framing these dynamics up front clarifies why granular segmentation, regional nuance, and tariff-related shifts demand focused analysis and why strategic agility is now a competitive imperative.

This introductory perspective sets the stage for a deep-dive that combines technological, commercial, and policy lenses, ensuring that readers appreciate how near-term operational decisions map to longer-term strategic outcomes across the influenza vaccine ecosystem.

How platform diversification, delivery innovation, and supply chain modernization are reshaping market dynamics and stakeholder strategies in influenza immunization

The landscape for influenza vaccines is undergoing transformative shifts that extend beyond incremental product updates to encompass manufacturing architectures, delivery modalities, and stakeholder collaboration models. Platform diversification is a central axis of change: inactivated vaccine production continues to optimize throughput and yield, while live attenuated and recombinant approaches attract attention for their potential to deliver broader immune responses and faster production cycles. Concurrently, the industry is witnessing greater emphasis on delivery formats that enhance ease of administration and reduce wastage, including prefilled syringes with differentiated materials and vial formats engineered for flexible dosing strategies.

Beyond product innovation, systemic changes are reshaping stakeholder behavior. Payers and public health authorities are looking to align immunization schedules with demographic risk profiling, prompting a more granular focus on age-group specific strategies. At the same time, contract manufacturing and fill-finish specialization are accelerating, enabling smaller innovators and regional manufacturers to scale without extensive capital investment in upstream antigen production. Supply chain digitization and cold chain modernization are enabling tighter inventory control and real-time visibility, reducing stockouts and enabling more responsive distribution models.

These shifts are accompanied by evolving regulatory and public health frameworks that prioritize rapid response capacity and equitable access. The cumulative effect is a market environment that rewards adaptability, cross-sector partnerships, and investment in both platform versatility and delivery optimization. Stakeholders that anticipate these changes and align capability development with emerging policy expectations will be positioned to capture value and support resilient immunization programs.

Assessing the multifaceted consequences of United States tariff changes in 2025 on sourcing strategies, manufacturing localization, and supply chain resilience within the vaccine value chain

The cumulative impact of tariff adjustments introduced by the United States in 2025 has rippled through the influenza vaccine ecosystem, influencing sourcing decisions, input costs, and supply chain design. Producers that relied on cross-border procurement of specialized consumables, syringe components, and fill-finish materials encountered higher landed costs and longer procurement cycles. This dynamic prompted a series of tactical responses, including supplier diversification, renegotiation of long-term contracts, and localized sourcing for critical components to mitigate the volatility introduced by trade policy changes.

These tariff-driven pressures also accelerated conversations around regional manufacturing capacity and onshoring strategies. Facilities designed for fill-finish operations became more attractive as a means to reduce exposure to cross-border tariffs on finished goods, while partnerships between antigen producers and regional contract manufacturing organizations increased to minimize tariff leakage. At the same time, manufacturers are evaluating cost-to-serve tradeoffs across presentation formats; for some organizations, multi dose vials with shared distribution costs become more economically viable, while others prioritize prefilled syringe formats that reduce administration time and wastage, accepting higher component costs to secure market differentiation.

Beyond direct cost implications, the tariff environment has heightened regulatory and contractual scrutiny. Procurement teams are revisiting clauses related to force majeure, pricing pass-through, and supply continuity, while regulators are engaging with industry to ensure that trade measures do not unintentionally hinder public health preparedness. The aggregate effect is a more cautious procurement stance, with increased investment in supply chain visibility, scenario planning, and vendor risk assessment. Entities that proactively adjust their sourcing strategies and contractual frameworks are better equipped to preserve continuity of immunization programs amid trade-related headwinds.

Segment-driven strategic insights revealing how vaccine type, age cohort, dosing, presentation, distribution channel, and end-user characteristics interact to shape commercialization and delivery

Insights derived from segmentation analysis reveal differentiated opportunity spaces and operational priorities across vaccine type, age group, dosage, presentation, distribution channel, and end-user contexts. Based on vaccine type, distinctions between inactivated, live attenuated, and recombinant approaches matter for manufacturing lead times, cold chain sensitivity, and clinical guidance, which in turn influence procurement cadence and clinical training needs. Based on age group, adult, geriatric, and pediatric cohorts require tailored communication strategies, dosing considerations, and outreach models to optimize uptake and minimize adverse event concerns.

Based on dosage, the contrast between multi dose and single dose strategies affects inventory management, wastage rates, and per-dose administration logistics, while based on presentation, preferences for prefilled syringe and vial formats shape procurement of ancillary supplies and training of administering staff; the prefilled syringe pathway further differentiates into glass prefilled syringe and plastic prefilled syringe options with distinct shelf-life and handling implications, and the vial pathway divides into multi dose vial and single dose vial choices that carry different cold chain and multi-use governance considerations. Based on distribution channel, the roles of direct sales and hospital pharmacies influence lead times, contract structures, and visibility into end-user consumption. Based on end user, clinics and hospitals present divergent operational rhythms and procurement behaviors, with clinics further segmented into outpatient clinics and specialty clinics, and hospitals further segregated into private hospitals and public hospitals, each with unique purchasing cycles, reimbursement frameworks, and storage capacities.

These segmentation-driven insights underscore that strategic choices cannot be made in isolation: product platform decisions interact with presentation formats and end-user capabilities, and distribution channel strategies must align with age-group priorities and dosing strategies. Effective commercialization and public health planning therefore require cross-functional alignment between manufacturing, regulatory, procurement, and field operations, ensuring that product portfolios and delivery strategies map to the operational realities of the settings where vaccines are administered.

Regional strategic considerations and operational differentiators across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine access and deployment strategies

Regional dynamics materially influence how influenza vaccine strategies are developed and executed, with distinct operational, regulatory, and market-access considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, procurement models and public health programs emphasize national immunization campaigns supported by robust cold chain infrastructure in urban centers, while rural access and equitable distribution remain critical focus areas; private sector channels and direct-supply agreements shape commercial approaches in several key jurisdictions.

In Europe, Middle East & Africa, regulatory harmonization efforts and cross-border procurement mechanisms are important determinants of supply continuity and market entry strategies. Regulatory agencies in Europe prioritize stringent pharmacovigilance and batch-release oversight, while several markets within the broader EMEA region present opportunities for capacity building in cold chain and distribution. Growing attention to vaccine sovereignty in parts of the region has catalyzed partnerships aimed at enhancing local manufacturing and fill-finish capabilities.

Asia-Pacific exhibits a heterogeneous landscape where advanced manufacturing hubs coexist with emerging markets that have growing demand and variable cold chain maturity. The region features strong domestic producers in some countries and rapidly expanding public health programs in others, resulting in diverse procurement models and distribution challenges. Cross-border logistics, regional trade arrangements, and local regulatory pathways shape how manufacturers and distributors prioritize investments and partnerships in the region. Across all regions, alignment between product offerings, presentation choices, and the operational capacities of end-user settings is essential for effective immunization coverage and program sustainability.

Corporate strategies and partnership ecosystems that combine platform innovation, specialized manufacturing, and integrated delivery solutions to secure competitive advantage

Competitive dynamics among companies across the influenza vaccine ecosystem reflect a blend of platform incumbency, innovation partnerships, and specialization in ancillary components and delivery technologies. Established vaccine producers are balancing legacy inactivated platform efficiencies with investment in recombinant and novel antigen technologies that offer faster responsiveness and potential immunogenic advantages. At the same time, contract manufacturing organizations and specialty fill-finish providers are gaining strategic importance by enabling flexible scale-up and regionalized production models that reduce exposure to cross-border trade shifts.

Adjacencies with device manufacturers-particularly those that specialize in prefilled syringe materials and syringe component supply-play a pivotal role in differentiating product offerings. Companies that integrate device and vaccine solutions can present compelling value propositions to purchasers seeking reduced administration time and lower wastage. Strategic partnerships between developers, contract manufacturers, and logistics specialists are becoming more common, facilitating end-to-end solutions that cover antigen production, fill-finish, packaging, and last-mile cold chain capabilities.

Commercial and regulatory strategies are also evolving: some organizations prioritize long-term procurement contracts and collaborative risk-sharing arrangements with public health authorities, while others pursue flexible commercial models and targeted launches in markets with favorable regulatory pathways. Firms investing in digital supply chain platforms, enhanced batch traceability, and pharmacovigilance capabilities are better positioned to meet heightened regulatory scrutiny and procurement expectations. Overall, companies that combine platform innovation, supply chain agility, and collaborative commercial models will stand out in a landscape where both product efficacy and delivery efficiency determine competitive advantage.

Practical recommendations for strengthening supply resilience, optimizing presentation strategies, and aligning procurement and regulatory approaches to accelerate vaccine access

Industry leaders should prioritize actions that strengthen resilience, accelerate delivery innovation, and align commercial models with public health goals. First, invest in supplier diversification and localization initiatives that reduce exposure to single-source dependencies and trade-policy volatility; this includes strategic relationships with contract manufacturers and targeted investments in regional fill-finish capacity to shorten lead times and improve supply security. Second, rationalize presentation portfolios by balancing the operational advantages of prefilled syringes against the cost and logistical benefits of vial formats, making these choices in light of end-user capabilities, age-group needs, and wastage considerations.

Third, integrate digital supply chain and inventory management tools to enhance visibility and enable proactive redistribution during demand fluctuations; real-time data can inform rapid decisions on allocation and reduce stockouts. Fourth, design procurement and contracting frameworks that incorporate contingency clauses, demand-flexibility terms, and collaborative risk-sharing to safeguard continuity while maintaining cost discipline. Fifth, pursue cross-sector partnerships that align manufacturers, payers, and health systems around shared objectives such as increasing uptake in under-immunized groups and streamlining administration pathways.

Finally, prioritize regulatory and quality investments that shorten time to market for new platforms and presentations, including early engagement with regulatory authorities and reinforcement of pharmacovigilance systems. By taking these steps, industry leaders can transform uncertainty into strategic opportunity, ensuring that vaccine portfolios and distribution strategies are robust, adaptable, and aligned with evolving public health imperatives.

A robust mixed-methods research methodology combining secondary analysis, expert primary interviews, supply chain mapping, and scenario testing to inform actionable insights

This research synthesizes qualitative and quantitative methods to generate actionable insights that reflect both macro-level trends and operational realities. The approach begins with comprehensive secondary research across peer-reviewed literature, regulatory publications, and public health guidance to create a baseline understanding of platform technologies, presentation formats, and policy frameworks. Primary research complements this foundation through structured interviews with subject-matter experts including manufacturing leaders, supply chain executives, clinicians, and procurement specialists to capture experiential insights and on-the-ground constraints.

Supply chain mapping and scenario analysis are used to test the implications of tariff shifts, presentation choices, and regional distribution models, with sensitivity analyses that examine how changes in sourcing, lead times, and logistics capacity affect operational risk profiles. The research also incorporates case study analysis of recent program rollouts and technology transitions to identify practical lessons in rollout planning, training, and wastage management. Quality assurance measures include cross-validation of primary interview findings with regulatory filings and publicly available procurement documentation, ensuring that conclusions are triangulated across multiple evidence streams.

Throughout the methodology, emphasis is placed on transparency and reproducibility: data sources and analytical assumptions are documented, and methodological limitations are acknowledged to guide interpretation. This mixed-methods approach ensures that strategic recommendations are grounded in both empirical evidence and practitioner expertise, making them relevant for decision-makers seeking implementable solutions.

A concluding synthesis emphasizing the imperative for integrated, segmentation-aware strategies across innovation, procurement, and distribution to ensure enduring vaccine access

In conclusion, the influenza vaccine ecosystem is at an inflection point where platform innovation, presentation choices, and supply chain resilience collectively determine program success. Stakeholders must navigate a complex set of tradeoffs: balancing the benefits of advanced recombinant or live attenuated technologies with the pragmatic realities of manufacturing capacity and distribution readiness, and reconciling the administrative efficiencies of prefilled syringe solutions with the cost and wastage dynamics of vial-based approaches. Tariff-related policy shifts have underscored the importance of sourcing diversification and regional manufacturing strategies, reinforcing the need for contractual and operational agility.

Effective responses require holistic strategies that span product development, procurement, and field implementation. By aligning segmentation-aware product strategies with regional operational capabilities, and by investing in digital visibility and collaborative commercial models, organizations can reduce risk and enhance access. The most successful actors will be those that treat the vaccine lifecycle as a system problem-one that demands integrated solutions across manufacturing, logistics, regulatory engagement, and end-user support. This systemic lens will be essential for translating technological advances into sustainable immunization outcomes and for ensuring that influenza vaccination programs meet public health objectives efficiently and equitably.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of mRNA technology applications in quadrivalent and universal influenza vaccine development
  • 5.2. Adoption of high-dose and adjuvanted vaccine formulations for enhanced immunogenicity in elderly populations
  • 5.3. Implementation of digital health platforms for real-time influenza vaccine efficacy monitoring and reporting
  • 5.4. Regulatory fast-track approvals and emergency use authorizations accelerating novel influenza vaccine candidates
  • 5.5. Strategic collaboration between pharmaceutical companies and local manufacturers to address regional vaccine shortages

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Influenza Vaccine Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Influenza Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Influenza Vaccine Market, by Dosage

  • 10.1. Multi Dose
  • 10.2. Single Dose

11. Influenza Vaccine Market, by Presentation

  • 11.1. Prefilled Syringe
    • 11.1.1. Glass Prefilled Syringe
    • 11.1.2. Plastic Prefilled Syringe
  • 11.2. Vial
    • 11.2.1. Multi Dose Vial
    • 11.2.2. Single Dose Vial

12. Influenza Vaccine Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Hospital Pharmacies

13. Influenza Vaccine Market, by End User

  • 13.1. Clinics
    • 13.1.1. Outpatient Clinics
    • 13.1.2. Specialty Clinics
  • 13.2. Hospitals
    • 13.2.1. Private Hospitals
    • 13.2.2. Public Hospitals

14. Influenza Vaccine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Influenza Vaccine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Influenza Vaccine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Sanofi S.A.
    • 17.3.2. CSL Limited
    • 17.3.3. GlaxoSmithKline plc
    • 17.3.4. AstraZeneca plc
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Sinovac Biotech Ltd.
    • 17.3.7. China National Pharmaceutical Group Co., Ltd.
    • 17.3.8. Serum Institute of India Private Limited
    • 17.3.9. Changchun BCH Bioengineering Co., Ltd.
    • 17.3.10. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. INFLUENZA VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GLASS PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PLASTIC PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY OUTPATIENT CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DOSAGE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PRESENTATION, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 335. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 336. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 337. ASEAN INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. ASEAN INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. ASEAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. ASEAN INFLUENZA VACCINE MARKET SIZE,